A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eisai Inc
- 12 Sep 2017 Planned primary completion date changed from 30 Jun 2019 to 31 Mar 2019.
- 10 Aug 2016 Planned number of patients changed from 21 to 90.
- 10 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Jun 2019.